{Reference Type}: Case Reports
{Title}: Association between sitagliptin plus vitamin D3 (VIDPP-4i) use and clinical remission in patients with new-onset type 1 diabetes: a retrospective case-control study.
{Author}: Pinheiro MM;Pinheiro FMM;de Arruda MM;Beato GM;Verde GACL;Bianchini G;Casalenuovo PRM;Argolo AAA;de Souza LT;Pessoa FG;Hirose TS;Senra EF;Ricordi C;Fabbri A;Infante M;Diniz SN;
{Journal}: Arch Endocrinol Metab
{Volume}: 67
{Issue}: 5
{Year}: 2023 May 25
{Factor}: 2.032
{DOI}: 10.20945/2359-3997000000652
{Abstract}: <B>UNASSIGNED: </B>The occurrence of partial remission (honeymoon phase) in type 1 diabetes (T1D) has been associated with a reduced risk of chronic microvascular complications of diabetes. We have published case reports showing that a combination therapy with the DPP-4 inhibitor sitagliptin plus vitamin D3 (VIDPP-4i) can prolong the honeymoon phase in patients with new-onset T1D. In the present case-control study, we investigated the frequency of occurrence of clinical remission (CR) in patients with new-onset T1D after VIDPP-4i treatment.<BR><B>UNASSIGNED: </B>In this case-control study, we collected data spanning 10 years from medical records of 46 patients (23 females) recently diagnosed with T1D. Overall, 27 participants with CR (insulin dose-adjusted glycated hemoglobin [IDAA1c] ≤ 9) at 12 or 24 months composed the case group, and 19 participants without CR served as the control group. Chi-square with Yates correction was used to analyze the association between VIDPP-4i use and CR, and odds ratio (OR) was used to determine the chance of CR due to VIDPP-4i treatment exposure.<BR><B>UNASSIGNED: </B>In all, 37 patients (80.4%) experienced CR at some time over 24 months. The mean CR duration was 13.15 ± 9.91 months. Treatment with VIDPP-4i was significantly associated with CR. At 24 months, the OR of CR after VIDPP-4i exposure was 9.0 (95% confidence interval [CI] 2.21-30.18, p = 0.0036). Additionally, 9 (33.6%) and 4 (14.8%) patients in the VIDPP-4i group experienced insulin-free CR at 12 and 24 months, respectively.<BR><B>UNASSIGNED: </B>Therapy with VIDPP-4i was associated with a higher frequency and duration of the honeymoon phase. Randomized controlled trials are needed to confirm these findings.